X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), in the EU.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 15, 2023
Details:
Braftovi (encorafenib) + Mektovi (binimetinib) is approved for the treatment of adult patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC), who are either treatment naïve or have received prior therapy.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Braftovi (Encorafenib) is an oral small molecule BRAF kinase inhibitor and is approved in combination with Mektovi (binimetinib) in patients with BRAF V600E-mutant metastatic non-small cell lung cancer.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
Braftovi (Encorafenib) Is An Oral Small Molecule Braf Kinase Inhibitor And Combination With Cetuximab Used for Patients With Patients With Braf V600E Alterations In Metastatic Colorectal Cancer.
Lead Product(s): Encorafenib,Cetuximab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2023
Details:
ERAS-007 is an oral ERK1/2 inhibitor. ERAS-007 + EC was generally well tolerated with mostly low-grade treatment-related adverse events (TRAEs) at all combination doses tested for the treatment of metastatic BRAF V600E- colorectal cancer.
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Braftovi (encorafenib) is an oral small molecule BRAF kinase inhibitor and MEKTOVI (binimetinib) is an oral small molecule MEK inhibitor which target key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK), for patients with metastatic non-small cell lung cancer.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
The agreement will support a clinical proof-of-concept trial evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the anti-EGFR antibody cetuximab for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2022
Details:
Zentalis and Pfizer will initiate a Phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib and cetuximab—an FDA-approved standard of care known as the BEACON regimen—in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC).
Lead Product(s): ZN-C3,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 24, 2022
Details:
23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or ERAS-601.
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Braftovi (encorafenib) is an oral small-molecule BRAF kinase inhibitor and binimetinib is an oral small-molecule MEK inhibitor that targets key enzymes in the MAPK signalling pathway (RAS-RAF-MEK-ERK).
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Organisation for Research and Treatment of Cancer
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
This agreement will support a clinical proof-of-concept study evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E-mutant mCRC.
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Erasca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2021
Details:
In this study, BRAFTOVI and cetuximab combination treatment group demonstrated a statistically significant extension in overall survival (OS), versus the control group (irinotecan and cetuximab based combination treatment).
Lead Product(s): Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2021
Details:
The partnership includes the planning, design and execution of a large Phase 3 study of Braftovi (encorafenib) investigating the use of BRAF and MEK targeted therapies to reduce the risk of relapse in this patient population, currently under approval with authorities.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EORTC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 29, 2021
Details:
Phase 3 BEACON CRC trial data showed that BRAFTOVI in combination with cetuximab significantly improved overall survival in patients with BRAFV600E-mutant mCRC and reduced the risk of death by 40%.
Lead Product(s): Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2020
Details:
BRAFTOVI plus cetuximab is the first-and-only FDA-approved targeted regimen specifically for adults with previously treated metastatic CRC with a BRAFV600E mutation.
Lead Product(s): Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
